Talk:Exenatide

message: Metformin is inexpensive, has low side effects (one side effect is weight loss) and may delay the onset of type 2 diabetes.  D Vadbunker, RN 17:57, 12 April 2006 (UTC)
replies: text: Actually, this comment was (in part) on topic.  D Vadbunker, RN (talk · contribs) explained their edit to the article.  They added the phrase 'except for metformin', which is still there 2 years and hundreds of edits later.  --Hroðulf (or Hrothulf) (Talk) 19:51, 15 April 2008 (UTC)
thread_title: Metformin

message: Added well-sourced, readable, practical instructions. Moved warnings to top. I did not change any of the scientific information, but moved the practical information (uses, warnings, technique) to the top. I believe a significant share of the audience for this article are looking for patient information in a form they can understand. They could easily be deterred by jargon laden science. Those looking for precise scientific details can scroll down; I haven't changed the scientific substance of the article, merely moved it to a lower section under "Chemistry and Pharmacology." 
I'll return tomorrow and clean thing up after a night's sleep. Improvements and suggestion welcome. Dave Burstein daveb  at dslprime.com. (I will also add a section on Byetta and weight loss, staying close to well-documented science.) db
DaveBurstein (talk) 05:24, 6 September 2008 (UTC)
replies: text: Thank you for you contributions, but Wikipedia articles should never be written from a second-person perspective—Wikipedia is an encyclopedia, and can't have instructional content. I have reworded most of your additions accordingly. Please don't let this discourage you from contributing :) Fvasconcellos (t·c) 20:17, 6 September 2008 (UTC)
thread_title: Major edit - added practical instructions

message: The BBC website is reporting a study based on a " new formulation" of Exenatide so that injections are only needed once a week instead of twice a day, also with fewer side effects.  http://news.bbc.co.uk/1/hi/health/7603676.stm   This also links to the lancet but you may have to log in and then do a search to find the article.  Soarhead77 (talk) 13:34, 8 September 2008 (UTC)
replies: text: Now mentioned in "Future research" section. Rod57 (talk) 13:07, 27 July 2010 (UTC)
thread_title:  Long acting Exenatide 

message: Some content needs moving to a more appropriate section. If no one else does it I'll have a go one day. Rod57 (talk) 05:55, 28 January 2010 (UTC)
thread_title:  Content needs rearranging 

message: The introduction of this article describes Exenatide as being administered "30 to 60 minutes before the first and last meal of the day" with a footnote pointing to the Byetta (Exenatide) package insert:
http://pi.lilly.com/us/byetta-pi.pdf
The Dosage and Administration section of this package insert describes Byetta (Exenatide) as administered "anytime within the 60-minute period before the morning and evening meals".  This section does not refer to a 30-minute period. The only references to 30 minutes within the package insert occur in under the "12 CLINICAL PHARMACOLOGY" section (12.3 Pharmacokinetics) where the package insert describes the impact of Byetta (Exenatide) on certain other medications taken within 30 minutes of the Byetta (Exenatide) dose.
For this reason I believe that the Introduction of the article should be corrected to refer to administration 60 minutes before the first and last meal of the day.  If no one else take care of this, and I don't encounter any feedback to the contrary, I will go ahead and make the change myself in a week or so.  —Preceding unsigned comment added by Reclarke (talk • contribs) 19:50, 18 May 2011 (UTC)
thread_title:  Introduction / Summary 

message: Gene therapies section is about disease not exenatide. Maybe move to type 2 diabetes ? - Rod57 (talk) 07:14, 11 June 2013 (UTC)
replies: text: It's also about the cost to users of Exenatide, so may become relevant when considering options.  By all means add this information to the type 2 diabetes article if necessary.  yoyo (talk) 03:47, 26 February 2017 (UTC)
thread_title:  Gene therapies section should not be in this article 

message: Did some members of FDA or EMA vote for or AGAINST Bydureon, and if yes, why? 
Any information about mortality vs. using only Metformin?
ee1518 (talk) 09:52, 15 May 2015 (UTC)
thread_title:  FDA vote for Bydureon? EMA vote for Bydureon? 

message: Just read this article, which hints that Parkinson's disease can be stopped by Exenatide. It's probably too early to add this to the article; however, it is something that may be watched closely in coming months.  Paine Ellsworth  put'r there  18:19, 5 August 2017 (UTC)
replies: text: It had been noted 4-Aug (incorrectly) in Medical Uses section (with Guardian ref), and deleted the same day. All probably based on this Lancet article, and reported on in New Scientist 12 Aug 2017. Could mention in a new Research section (the old one having been deleted) ? - Rod57 (talk) 17:19, 2 October 2017 (UTC)
thread_title:  Parkinson's disease 

message: Hello fellow Wikipedians,
I have just modified one external link on Exenatide. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:
*Added archive https://web.archive.org/web/20080820232725/http://pi.lilly.com/us/byetta-pi.pdf to http://pi.lilly.com/us/byetta-pi.pdf
When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.
Cheers.—InternetArchiveBot (Report bug) 04:43, 26 September 2017 (UTC)
thread_title:  External links modified